NVDA
NVIDIA
-- 131.760 TSLA
Tesla
-- 396.360 RGTI
Rigetti Computing
-- 8.9500 AMD
Advanced Micro Devices
-- 116.090 PLTR
Palantir
-- 65.910 
News
$BioAtla (BCAB.US)$ Reuters· just
Bioatla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (Cab-Ror2-ADC) for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Bioatla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (Cab-Ror2-ADC) for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Discussing
Trump 2.0 countdown: What's the next big opportunity in the markets?
▪️Could Trump's cryptocurrency policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese
Popular on moomoo
Jan 13 17:43
Trump 2.0 Opportunity Preview: Guess the market winner before the president takes office!